Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
出版年份 2015 全文链接
标题
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 112, Issue 11, Pages E1288-E1296
出版商
Proceedings of the National Academy of Sciences
发表日期
2015-03-04
DOI
10.1073/pnas.1411848112
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer
- (2014) E. E. Gardner et al. CANCER RESEARCH
- Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing
- (2014) David G. McFadden et al. CELL
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
- (2013) Claire L. Cope et al. JOURNAL OF CELL SCIENCE
- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- (2013) A. C. Faber et al. Cancer Discovery
- The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
- (2012) Matthew J. Sale et al. BIOCHEMICAL JOURNAL
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
- (2012) Antonio Rossi et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
- (2012) Charles M Rudin et al. NATURE GENETICS
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
- (2011) S. Al-harbi et al. BLOOD
- Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung
- (2011) Kate D. Sutherland et al. CANCER CELL
- Nuclear factor I/B is an oncogene in small cell lung cancer
- (2011) A. L. Dooley et al. GENES & DEVELOPMENT
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma
- (2011) Jonathan H. Schatz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
- (2011) Paul K. Paik et al. LUNG CANCER
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma
- (2010) J. J. Hwang et al. CLINICAL CANCER RESEARCH
- Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK
- (2010) F McCoy et al. Cell Death & Disease
- Small Cell Lung Cancer: Past, Present, and Future
- (2010) Estelamari Rodriguez et al. Current Oncology Reports
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
- (2008) C. L. Hann et al. CANCER RESEARCH
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
- In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
- (2008) K. D. Mason et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 promotes survival through translational control of Mcl-1
- (2008) J. R. Mills et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More